Grufity logoGrufity logo

Lexaria Bioscience Corp Stock Research

LEXX

2.86USD-0.01(-0.35%)Delayedas of 25 Jan 2023, 03:52 pm

Market Summary

USD2.86-0.01
Delayedas of 25 Jan 2023, 03:52 pm
-0.35%

LEXX Stock Price

LEXX RSI Chart

LEXX Valuation

Market Cap

16.4M

Price/Earnings (Trailing)

-2.25

Price/Sales (Trailing)

64.08

EV/EBITDA

-2.64

Price/Free Cashflow

-3.35

LEXX Price/Sales (Trailing)

LEXX Profitability

Return on Equity

-91.45%

Return on Assets

-92.79%

Free Cashflow Yield

-29.82%

LEXX Fundamentals

LEXX Revenue

Revenue (TTM)

255.4K

Revenue Y/Y

258.31%

Revenue Q/Q

11.47%

LEXX Earnings

Earnings (TTM)

-7.3M

Earnings Y/Y

-18.74%

Earnings Q/Q

42.16%

Price Action

52 Week Range

1.804.83
(Low)(High)

Last 7 days

3.2%

Last 30 days

17.1%

Last 90 days

38.7%

Trailing 12 Months

-33.3%

LEXX Financial Health

Current Ratio

35.96

LEXX Investor Care

Shares Dilution (1Y)

3.92%

Financials for Lexaria Bioscience

Income Statement (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-31.4%255372489606723
Gross Profit47.6%184124187325547
Operating Expenses7.4%7,5677,0487,3296,234-
  S&GA Expenses6.6%5,7255,3715,8805,7724,971
  R&D Expenses-4.3%1,8431,9261,6291,5291,263
EBITDA0%-1,711.87-1,711.87---
EBITDA Margin0%-2.37*-2.37*---
EBT Margin0%-2.52*-2.52*---
Net Income-3.6%-7,269.32-7,015.36-7,163.58-5,333.69-4,036.56
Net Income Margin-191.8%-28.46*-9.75*-9.94*--
Free Cahsflow-2.0%-4,879.34-4,781.95-4,690.51--
* denotes actual numbers (not divided by Thousands)
Balance Sheet
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-14.3%7,8349,13811,41511,74613,267
  Current Assets-15.8%6,9788,29110,57210,90112,443
    Cash Equivalents-17.6%5,8137,0518,3599,68210,918
  Inventory-4.4%3840322730
  Net PPE-8.1%316343368--
Liabilities-10.5%201225195277203
  Current Liabilities-6.2%194207166238153
Shareholder's Equity-13.4%7,9499,18311,22011,46913,266
  Retained Earnings-3.9%-39,098.53-37,631.06-35,248.14-33,822.36-31,829.20
  Additional Paid-In Capital0.5%47,04146,80946,69745,49845,089
Accumulated Depreciation7.9%380352278--
Shares Outstanding0%5,9515,9515,9515,7275,727
Minority Interest-16.9%-316.41-270.72-235.31-212.41-202.08
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-1.3%-4,879.34-4,814.91-4,712.49-4,346.47-3,989.68
  Share Based Compensation44.8%753520753770410
Cashflow From Investing-38.3%-180.64-130.60-163.37141194
Cashflow From Financing-101.1%-44.603,9714,01613,41813,420

Risks for LEXX

What is the probability of a big loss on LEXX?

100%


Probability that Lexaria Bioscience stock will be more than 20% underwater in next one year

100%


Probability that Lexaria Bioscience stock will be more than 30% underwater in next one year.

100%


Probability that Lexaria Bioscience stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does LEXX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Lexaria Bioscience was unfortunately bought at previous high price.

Drawdowns

Returns for LEXX

Cumulative Returns on LEXX

0.6%


10-Year Cumulative Returns

-42.4%


3-Year Cumulative Returns

What are the long-term rolling returns for LEXX?

FIve years rolling returns for Lexaria Bioscience.

Annualized Returns

Which funds bought or sold LEXX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
sold off
-
-
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
sold off
-
-
-
-%
2022-11-14
BOOTHBAY FUND MANAGEMENT, LLC
unchanged
-
-42,000
193,000
-%
2022-11-14
Centiva Capital, LP
reduced
-6.36
-10,000
32,000
-%
2022-11-14
ADVISOR GROUP HOLDINGS, INC.
unchanged
-
-2,000
5,000
-%
2022-11-14
Invenomic Capital Management LP
added
29.54
71,000
1,159,000
0.10%
2022-11-14
WELLS FARGO & COMPANY/MN
added
0.19
-1,000
2,000
-%
2022-11-14
SABBY MANAGEMENT, LLC
reduced
-16.93
459,000
699,000
0.88%
2022-11-14
Empery Asset Management, LP
unchanged
-
-14,000
74,000
0.44%
2022-11-14
GEODE CAPITAL MANAGEMENT, LLC
reduced
-1.85
-28,000
120,000
-%

1–10 of 26

Latest Funds Activity

Are funds buying LEXX calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own LEXX
No. of Funds

Lexaria Bioscience News

Yahoo Finance

Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor.

Yahoo Finance,
2 days ago

StreetInsider.com

Form 424B2 UBS AG.

StreetInsider.com,
8 days ago

InvestorsObserver

Yahoo Finance

InvestorsObserver

Proactive Investors USA

Scenari Economici

Schedule 13G FIlings of Lexaria Bioscience

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2022
invenomic capital management lp
6.03%
359,113
SC 13G
Feb 14, 2022
l1 capital global opportunities master fund, ltd.
2.6%
159,000
SC 13G/A
Feb 24, 2021
bunka christopher
9.5%
489,455
SC 13D/A

LEXX Fair Value

Recent SEC filings of Lexaria Bioscience

View All Filings
Date Filed Form Type Document
Jan 23, 2023
8-K
Current Report
Jan 18, 2023
10-Q/A
Quarterly Report
Jan 17, 2023
10-Q
Quarterly Report
Jan 17, 2023
8-K
Current Report
Dec 29, 2022
EFFECT
EFFECT
Dec 28, 2022
POS AM
POS AM
Dec 22, 2022
EFFECT
EFFECT
Dec 21, 2022
POS AM
POS AM
Dec 06, 2022
10-K/A
Annual Report
Nov 30, 2022
8-K
Current Report

Latest Insider Trading transactions for LEXX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-10-14
Downey Gregory
acquired
252.89
2.09
121
chief financial officer
2022-10-14
Downey Gregory
bought
252.89
2.09
121
chief financial officer
2022-10-13
BUNKA CHRISTOPHER
acquired
34,860
2.1
16,600
ceo
2022-10-13
BUNKA CHRISTOPHER
bought
34,860
2.1
16,600
chief executive officer
2022-10-12
BUNKA CHRISTOPHER
acquired
43,537.2
1.988
21,900
ceo
2022-10-12
BUNKA CHRISTOPHER
bought
43,537.2
1.988
21,900
chief executive officer
2022-05-24
REESE ALBERT L JR
acquired
9,790
1.958
5,000
-
2022-05-20
REESE ALBERT L JR
acquired
3,610.59
2.007
1,799
-
2022-05-19
REESE ALBERT L JR
acquired
3,017.01
2.01
1,501
-
2022-05-18
REESE ALBERT L JR
acquired
3,413.6
2.008
1,700
-

1–10 of 10

About Lexaria Bioscience

Christopher A. Bunka
6
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

LEXX Income Statement

2022-11-30
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended
Nov. 30, 2022
Nov. 30, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)  
Revenue$ 101,476$ 13,880
Cost of Goods Sold15,7955,570
Gross profit85,6818,310
Expenses  
Research and development829,489458,709
Office and administration1,025,4981,553,083
Total operating expenses1,854,9872,011,792
Net loss(1,769,306)(2,003,482)
Net loss for the period(1,769,306)(2,003,482)
Net loss and comprehensive loss attributable to:  
Common shareholders(1,755,944)(1,993,157)
Non-controlling interest$ (13,362)$ (10,325)
Basic and diluted income (loss) per share$ (0.30)$ (0.35)
Weighted average number of common shares outstanding  
Basic and diluted$ 5,950,998$ 5,726,699

LEXX Balance Sheet

2022-11-30
CONSOLIDATED BALANCE SHEET - USD ($)
Nov. 30, 2022
Aug. 31, 2022
Current  
Cash$ 4,533,063$ 5,813,218
Marketable securities269,707347,335
Accounts receivable286,322201,784
Inventory9,93638,418
Prepaid expenses and deposit260,342576,761
Total Current Assets5,359,3706,977,516
Non-current assets, net  
Right of use assets42,34052,444
Intellectual property500,549488,462
Property & equipment311,221315,505
Total Non-current Assets854,110856,411
TOTAL ASSETS6,213,4807,833,927
Current  
Accounts payable and accrued liabilities241,891151,449
Lease payable39,62942,587
Total Current Liabilities281,520194,036
Long Term  
Lease payable07,401
Total Long Term Liabilities07,401
TOTAL LIABILITIES281,520201,437
STOCKHOLDERS' EQUITY  
Authorized 220,000,000 common voting shares with a par value of $0.001 per share Issued and outstanding: 5,950,998 common shares at November 30, 2022 and at August 31, 20225,9515,951
Additional paid-in capital47,110,25747,041,481
Deficit(40,854,472)(39,098,528)
Equity attributable to shareholders of the Company6,261,7367,948,904
Non-controlling Interest(329,776)(316,414)
Total Stockholders' Equity5,931,9607,632,490
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$ 6,213,480$ 7,833,927